Recent development of antiangiogenic therapy for renal cell carcinoma (RCC) has significantly improved the treatment of these often refractory tumors. However, not all patients respond to therapy and assays for predicting outcome are needed. As a first step, we analyzed a retrospective cohort of tumors and assessed the ability of VEGF and VEGF receptors (VEGF-R1, -R2 and -R3) to classify tumors. We analyzed tissue microarrays containing 330 RCCs using a novel method of automated quantitative analysis of VEGF and VEGF-R expression by fluorescent immunohistochemistry. Expression of markers was separately quantified within three tissue components: tumor cells, endothelial cells and adjacent normal epithelium. VEGF and VEGF receptors were tightly coexpressed both within tumors and within adjacent normal cells (all P-values o0.001). Tumor cell expression of VEGF-R1 and -R2 was strongly and inversely correlated with vessel area (Po0.0001). Despite the recent success in treating advanced renal cell carcinoma (RCC) with antiangiogenic therapies, surprisingly little is known about expression of targets of these drugs in renal tumors and microvessels. There is some evidence to suggest that antiangiogenic agents target the microvasculature, 1 but they may also target autocrine growth factor pathways within the tumor cells themselves. Two multitarget tyrosine kinase inhibitors have been approved by the Federal Drug Administration for use in unresectable RCC: sorafenib (Bayer Pharmaceuticals, Leverkusen, Germany and Onyx Pharmaceuticals, Emeryville, CA, USA) and sunitinib (Pfizer Inc., New York, NY, USA). Additional inhibitors of the VEGF pathway are in clinical trials. Sorafenib inhibits members of the RAF pathway, as well as VEGF-R2 (KDR/Flk-1), VEGF-R3 (Flt-4) and PDGFR-b, and sunitinib inhibits VEGF-R2, PDGFR-b, Kit and Flt-3. Temsirolimus (Wyeth Pharmaceuticals, Madison, NJ, USA), an mTOR inhibitor, was also approved for advanced RCC and additional VEGF-R pathway-targeting agents are in clinical development.
The advent of these antiangiogenic agents into the clinic for RCC was preceded by advances in our understanding of tumor vasculature. Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene have been found in approximately 75% of clear cell RCCs, 2 resulting in induction of hypoxia-regulated genes in tumor cells, including VEGF. [3] [4] [5] Additional steps are required for vessel formation, including loss of integrity of the extracellular matrix. 6 Thus, inhibition of tumor angiogenesis is likely to require agents that target both the vessels and the malignant cells, as is evident by the lack of efficacy of monotherapy that directly targets VEGF. 1 Coupled with the clinical development of VEGF-Rtargeting therapies, there is an urgent need to develop biomarkers that predict response to these agents, as clearly only a subset of patients derive benefit from the drugs. Increased clinical benefit has been shown in patients who harbor VHL mutations, although other patients also derive benefit. 2 Additional approaches have been attempted to identify predictors of response, including assessment of target expression in tumor cells and tumor vasculature, interstitial fluid pressure, tumor oxygen tension, blood circulating endothelial cells, serum protein levels (such as VEGF) and imaging strategies that measure blood flow, as summarized by Jain et al. Immunohistochemistry (IHC)-based analysis of tumors is a practical approach to take for biomarker identification and validation, as IHC can be performed on small amounts of paraffin-embedded tissue. The typical first step in biomarker development is characterization of the biomarker in the disease population. Several studies have assessed expression of VEGF and VEGF receptors in RCC tumor cells; however few have separately analyzed the endothelial cell component, and none has used quantitative IHC to compare VEGF/ VEGF-R within these different tumoral elements. Mertz et al 7 have used automated analysis to assess the microvessel density of RCC and found associations with aggressive disease, but did not look at the VEGF/VEGF-R pathway. Tsuchiya et al 8 assessed expression of VEGF, VEGF-R1 (Flt-1) and VEGF-R2 in RCC tumor, adjacent normal renal tissue and endothelial cells by standard IHC and RT-PCR. However, their analyses only included 23 cases, and no association was made with clinical/pathological variables. Other smaller studies assessing VEGF/VEGF-Rs and microvessel density have been conducted. [9] [10] [11] Jacobsen et al 12 assessed a relatively large cohort tissue microarray (TMA) for VEGF expression, but no assessment of VEGF-R expression and microvessel density was made. Our purpose was to assess expression of VEGF, VEGF-R1, VEGF-R2 and VEGF-R3 in three tissue components: RCC cells, endothelial cells and adjacent normal renal tissue on a large patient cohort with associated clinical/ pathological data. We also assessed vessel area (VA) in the tumors. To obtain more accurate, objective measures of expression, we used our new method of automated quantitative analysis (AQUA). This method has been validated, and can be more accurate than pathologist-based scoring of brown stain. 13, 14 As with some targeted therapies, it is possible that response to VEGF-or VEGF-R-targeting drugs might be associated with expression levels of targets in tumors or stroma, and quantitative assays need to be developed to predict response. Other markers that have both prognostic and predictive value have significantly impacted our ability to appropriately select therapeutic regimens for other cancers, and similar assays might be beneficial in selection of RCC patients for antiangiogenic therapies.
MATERIALS AND METHODS
Tissue Microarray Construction TMAs were constructed as described. 14 
Immunohistochemistry
For analysis of markers in tumor cells and normal epithelium, TMAs were stained with a cocktail of anti-cytokeratin and streptavidin (which binds endogenous biotin) and visualized with a green fluorophore (Alexa 488), in conjunction with an antibody to the target marker (VEGF or VEGF-R1, -R2 or -R3). Target markers were visualized by incubating with an appropriate horseradish peroxidase-conjugated secondary antibody and Cyanine-5 tyramide. Cyanine-5 was used because its far-red emission spectrum is outside of the range of tissue autofluorescence. For analysis of markers in microvessels, TMAs were stained with CD34 in conjunction with an antibody to the target marker. Details of methods and antibodies appear in the Supplementary Materials.
Automated Image Acquisition and Analysis
Images were acquired and analyzed using algorithms that have extensively been described. 13 Briefly, monochromatic, high-resolution (1280 Â 1024 pixel) images were obtained of each histospot. Tumor was distinguished from stroma by the cytokeratin/streptavidin signal, and endothelial cells were distinguished using CD34. The target signal (VEGF, VEGF-R1, -R2 and -R3) from the tumor cells, adjacent normal epithelium or endothelial cells was scored on a scale of 0-255, and expressed as the average signal intensity within the assayed component (AQUA score). Histospots containing o3% tumor were excluded from further analysis. VA was calculated as the percent area of CD34 mask within a histospot.
Statistical Analysis
The StatView (SAS Institute Inc., Cary, NC, USA) and R 15 software packages were used. AQUA scores for replicate tumor cores were averaged. Unsupervised hierarchical clustering was performed using TreeView and Cluster software. 16 For clustering, AQUA scores were converted into z-scores and analysis was limited to cases with scores for 480% of markers. 17 The prognostic significance of parameters was assessed for predictive value using the Cox proportional hazard model (PHM) with RCC-specific survival as an end point. Kaplan-Meier survival curves were generated for patient subsets defined by the cluster analyses, with significance evaluated using the Mantel-Cox log-rank test and multivariate Cox PHMs. Correlations between markers were assessed using the Spearman's r-test. Variables were univariately and bivariately entered into Cox PHMs to assess the significance at a ¼ 0.05. To evaluate whether individual variables and combinations of variables are able to predict if a patient died of disease or was alive at 10 years, leave-one-out cross-validation (LOOCV) was employed with logistic regression models. This form of cross-validation iteratively splits the N observations into a training set of size NÀ1 and a test set of size 1. At each iteration the coefficients for the logistic model are estimated based on NÀ1 observations in the training set, and used to predict the one observation in the test set. Misclassification was assessed based on whether the observation is incorrectly or correctly predicted. The model's prediction performance, or error, was calculated as the average misclassification over the N iterations. The lower the average misclassification, the better the prediction. 18 Confidence intervals (CIs) for prediction error estimates were constructed by nonparametric bootstrap resampling. 19 See Supplementary Information for details.
RESULTS
VEGF and VEGF-R staining was localized to the cell membrane and cytoplasm of tumor cells, normal tubules and endothelial cells, with no significant nuclear staining. An example of VEGF-R3 staining within endothelial and tumor cells is shown in Figure 1 .
To account for intratumor heterogeneity, two separate sets of slides, each containing a core from a different area of the tumor for each patient, were used to evaluate expression of each marker. We assessed the correlation between the two cores for each marker and for VA using the Spearman's r-test. All scores from the two cores for the different markers within the tissue compartments correlated well (Po0.0001), and examples are given in Figure 2a -c. Scores from corresponding cores were averaged to obtain a single concatenated score for each marker. The mean AQUA scores and the significance of the association with nuclear grade and stage by unpaired t-tests are shown in Table 1 . Most notably, high VEGF/ VEGF-R expression in tumor cells was associated with high nuclear grade, as were high VEGF-R3 in vessels and VA. High VEGF-R2 in tumor and normal kidney, high VEGF-R3 in vessels and low VA were associated with stage III/IV disease. VEGF-R levels were higher on tumor cells than normal epithelium, and higher on tumor vessels than normal vessels (see Supplementary Table 2 for paired t-test P-values).
We assessed associations between markers by Spearman's r-test, as demonstrated in Figure 2d . Red squares represent positive correlations, and green represent anticorrelations. Squares with yellow perimeters represent strong associations between markers (Po0.0004). We found strong coordinated expression of VEGF and VEGF-Rs within each tissue compartment, and a strong anticorrelation between VEGF-R1 and -R2 in tumor cells and VA. Table 2 shows a multivariate regression model of the association between expression of VEGF and VEGF receptors on tumor and endothelial cells and VA. Expression of VEGF-R1 and -R2 on tumor cells was strongly and independently anticorrelated with VA, whereas high expression of VEGF-R3 on endothelial cells was strongly and independently correlated with VA.
By Cox univariate analysis of raw AQUA scores, we assessed the associations between markers and RCC-specific survival, as shown in Table 3 . Markers associated with decreased survival include high stage, high nuclear grade, high tumor VEGF, VEGF-R1, -R2 and -R3, high VEGF-R3 in vessels, low tumor VA and low VEGF in adjacent normal kidney.
To assess the ability of each marker to predict patient outcome, we used LOOCV to calculate misclassification rates. Patients were dichotomized as either died of RCC at 10 years or alive at 10 years. Misclassification rates for each of the markers ranged from 0.24 to 0.27, comparable to stage or grade (Table 3) . However, none of the markers, or stage or grade, produced misclassification rates that were below the 95% CI of the null model. Note that in many cases, analyzing the ratio of tumoral expression to normal epithelial expression improved the misclassification rate.
We performed unsupervised hierarchical clustering of tumors by expression of VEGF/VEGF-Rs in tumor cells, microvessels and adjacent kidney. Markers clustered into three groups: those from tumor cells (red), normal epithelium (green), and microvessels (blue) (Figure 3a) . Microvessels clustered together regardless of their original location (tumor or adjacent normal kidney). Tumors were classified into six distinct clusters: (1) low expression of all markers in tumor, normal kidney and microvessels (blue); (2) high in normal and low in tumor (green); (3) singularly high levels of VEGF-R3 in tumor and normal cells (pink); (4) high tumor and microvessel expression (orange); (5) high in tumor only (red) and (6) unclassified (black). We then determined if clusters had significant differences in VA. Clusters with low VEGF/ VEGF-R tumor expression (blue and green) were associated with higher VA (Figure 3b ). There was no clear association between cluster assignment and pathological subtype (Figure 3c ). We note, for example, that 28% of clear cell cases were assigned to the blue cluster, compared to 20.5% of the papillary cases, but the number of cases in all nonclear cell subtypes was small, and definitive conclusions cannot be drawn. Two clusters (orange and red) with high tumor expression of VEGF/VEGF-Rs exhibited worse survival by Kaplan-Meier analysis (P ¼ 0.0007; Figure 3d ). 
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On multivariable analysis, assignment to a cluster with high VEGF/VEGF-R was an independent predictor of poor survival, as were nuclear grade and stage (Table 4) . Cluster assignment of the clear cell RCC patient subset produced similar results by Kaplan-Meier analysis, and was similarly significant on multivariable analysis (Supplementary Figure 2) .
Next we assessed whether the addition of one or more markers in the VEGF/VEGF-R family could improve the misclassification rate of stage and grade (Figure 4) . The ratio of VEGF-R1 in tumor vs normal, which lowered the misclassification rate from 26 to 18.3%, had the largest impact of all markers (Figure 4a ). As expression of VEGF/VEGF-Rs is tightly associated in tumors, we were interested in interactions between these molecules that might have significant positive or negative associations with survival. We noted two such interactions: (1) a positive interaction between VEGF and VEGF-R1, and (2) a negative interaction between VEGF-R2 and VEGF-R1 (Figure 4b and c) . The combination of these two interactions in a logistic multivariate model with stage and grade reduced the misclassification rate to 17.4% (Figure 4a ).
DISCUSSION
We quantitatively assessed VA and expression of VEGF/ VEGF-Rs in tumor, endothelial cells and adjacent normal renal tissue on a large cohort of RCC patients, and evaluated the association between expression and RCC-specific survival. AQUA gives objective, continuous measures of expression, rather than arbitrary pathologist-based divisions of staining into ordinal scores, or 'high/low' , and can separately assess expression in different tumor components (eg, microvessels). Expression of VEGF and VEGF receptors, particularly VEGF-R1 and VEGF-R2, was highly correlated within each tissue component. Expression patterns were very similar in endothelial cells within the tumor and within the adjacent normal kidney, presumably because the vessels originate from the same primary cells. No clear differences in expression patterns were seen based on histological subtypes. Expression of VEGF/VEGF-Rs in tumors was strongly associated with nuclear grade, and these markers individually were not independent predictors of survival.
Unsupervised hierarchical clustering of samples based on expression patterns of markers in the tissue components revealed distinct patient clusters with divergent outcome; most notably, patients with high VEGF and VEGF-Rs in tumor cells had worse outcome when compared to the other clusters. The expression of VEGF-Rs on tumor vessels did not affect outcome. This classification of patients retained its prognostic significance on multivariable analysis and improved the misclassification rates of models that contained nuclear grade and stage.
One potential disadvantage of TMAs as opposed to whole tissue specimens is the difficulty in assessing heterogeneity of tumors. Of particular concern is the possibility that different areas of tumors might have different VA. Here we demonstrate a remarkably strong correlation between VAs from the two histospots from the same patient. We also found strong intrapatient correlations for expression of all the markers studied.
The reason for the anticorrelation between expression of VEGF-R1 and -R2 in tumor cells and VA is unknown, but may involve a 'steal' effect where tumors with high VEGF-R expression bind VEGF before it can be secreted to promote neovascularization. VEGF-R3 on endothelial cells was positively correlated with VA, as expected. Smaller studies by others have shown variable associations between clinical outcome and microvessel density. 10, 20 Kurban et al 6 showed that VHL mutations resulting in upregulation of HIF1a are associated with decreased microvessel density and low invasive potential, consistent with our results.
Our findings of an association between high VEGF-R1 and -R2 levels in tumor cells and decreased survival are contrary to those of Ljungberg et al, 11 who assessed mRNA levels of these receptors in 104 patients. The difference might be related to sample size, inconsistencies between mRNA and protein levels and inclusion of stromal elements when performing RT-PCR on snap-frozen specimens.
Staging of RCC is important for determining prognosis and selecting high-risk patients for systemic therapies as they become available. For example, patients with stage III tumors have cure rates of 38-70% with nephrectomy alone, and 21 Ideally these investigations should focus on patients with the worst prognosis. At present there are no approved adjuvant therapies for RCC, but a large phase III randomized trial is underway comparing sunitinib, sorafenib and placebo. Molecular markers in primary specimens highly associated with survival, such as profiles of high VEGF/VEGF-Rs, could improve staging for nonmetastatic patients, and enable us to identify high-risk patients more likely to benefit from adjuvant therapy, thus avoiding toxicity for patients who could be cured by resection alone. 22 In addition to a potential role as a prognostic classifier, our findings have very important implications for therapeutic applications of VEGF and VEGF-R inhibitors in RCC. Metastatic RCC has been traditionally a dismal disease, due to resistance to chemotherapy. However, sunitinib and sorafenib have dramatically revolutionized the therapeutic approach to metastatic RCC. As with some other targeted Figure 4 Misclassification rates of multivariate logistic models. All models were calculated using dead of disease at 10 years as a binary variable. Makers were assessed as a ratio of tumor expression to normal epithelial expression (D). All models included stage and grade. The ability of various models to predict outcome was assessed using LOOCV (a). 95% confidence intervals are shown in black (lower) and gray (upper). Analysis of stage and grade improves the misclassification of outcome from 26 (using a null model) to 19.6%. Adding VEGF or VEGF-Rs to this model does not significantly improve the misclassification rate. Two interesting interactions were noted: (b) shows that the ability of VEGF to predict outcome (y axis) improves on tumors with higher levels of VEGF-R1 (x axis). Without taking VEGF-R1 into account, the odds ratio for VEGF is 1.49 (dashed line). In contrast, (c) shows the ability of VEGF-R2 to predict outcome improves on tumors with lower VEGF-R1 levels. The dashed line shows the odds ratio of VEGF-R2 without the R1 interaction (0.71). The addition of the interactions outlined in panels b and c improves the misclassification rate to 17.4% (a).
therapies, there might be an association between target expression and response to therapy. It is yet unclear whether sunitinib and sorafenib inhibit RCC tumor growth by affecting tumor epithelial cells, endothelial cells or proangiogenic functions of adjacent normal kidney. In our retrospective cohort of clinical specimens there is variability in VEGF/VEGF-R expression, and expression patterns define distinct groups of patients with clear differences in prognosis. Our results show that high VEGF/VEGF-R in tumor cells is predominantly associated with poor survival. On the other hand, patients whose tumors have higher VA have improved survival, and lower levels of VEGF/VEGF-R in their tumor cells. Studies are needed to determine whether agents that target VEGF-R2 are more likely to be effective in patients whose tumor cells have higher target expression (and thus decreasing proliferation of tumor cells) or in patients whose tumors are more vascular and have lower levels of VEGF-Rs in tumor cells. Moreover, it is possible that small molecule inhibitors that target the receptors might be effective in a different subset of patients than those that will benefit from VEGF-targeting agents such as bevacuzumab. Given that sunitinib and sorafenib only benefit a subset of metastatic RCC patients, 23, 24 improved patient selection based on predictive biomarkers might improve the therapeutic ratio of these agents, as administration of these drugs is associated with some toxicity. Our studies have only addressed the expression of VEGF/VEGF-Rs on primary tumors. We are currently assessing whether metastatic tumor deposits express VEGF/VEGF-R levels at the same or different levels than the primary tumors from which they arose.
Some of the studies of sunitinib and sorafenib in RCC excluded nonclear cell subtypes. Our data show no clear differences in expression patterns of VEGF-Rs between the histological subtypes, suggesting that targeting these receptors might be effective in other RCC subtypes as well, as recently reported. 25 In summary, our study shows that VEGF and VEGF receptors exhibit a complex pattern of coordinated expression in RCC. Although our observations were made in an untreated patient population, they may have significant therapeutic implications in the selection of antiangiogenic therapies for the tumors in different clusters. Clustering of tumors based on VEGF and VEGF receptors in tissue components may provide a prognostic assay and might also provide a means for determining which tumors will respond to what antiangiogenic therapies. Prospective studies are needed to confirm the prognostic role of VEGF and VEGF-R expression patterns, as well as the predictive value of expression patterns in patients treated with VEGF pathwaytargeting agents, preferably using quantitative methods of protein measurement. Future clinical trials incorporating these agents for RCC should stratify patients based on VEGF/VEGF-R expression, with the goal of developing an assay for improved patient selection for antiangiogenic agents.
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